{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Membrane Transporter & Ion Channel > Zosuquidar triHydrochlorideCAS：167465-36-3
Molecular Formula：C32H31F2N3O2·3HCl
Molecular Weight：636.99
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 167465-36-3 |
| Name | Zosuquidar triHydrochloride |
| Molecular Formula | C32H31F2N3O2·3HCl |
| Molecular Weight | 636.99 |
| Solubility | Soluble in Water ≥1mg/mL(Need ultrasonic or Water bath) |
| Purity | ≥98% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00942300 |
| SMILES | FC1([C@H]2[C@@H]1C3=C([C@@H](C4=CC=CC=C42)N5CCN(CC5)C[C@H](COC6=C7C=CC=NC7=CC=C6)O)C=CC=C3)F.Cl.Cl.Cl |
| Target Point | P-gp(P-glycoprotein) |
| Passage | Membrane Transporter&Ion Channel |
| Background | Zosuquidar trihydrochloride is an inhibitor of P-glycoprotein. |
| Biological Activity | Zosuquidar trihydrochloride是P-糖蛋白(P-gp)的抑制剂， Ki值为59 nM。[1-5] |
| Data Literature Source | [1]. Cripe LD，et al. Zosuquidar，a novel modulator of P-glycoprotein，does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized，placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 201 [2]. Tang R，et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AmL). BMC Cancer. 2008 Feb 13;8:51. [3]. Kemper EM，et al. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol. 2004 Feb;53(2):173-8. [4]. Anderson BD，et al. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metab Dispos. 2006 Apr;34(4):653-9. [5]. Hou J，et al. Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012 Jul;66:232-9. |
| Unit | Bottle |
| Specification | 5mg 10mg 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
